Symbols / VYGR Stock $3.62 -1.77% Voyager Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
VYGR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 218.42M
Enterprise Value 115.44M
Income -116.64M
Sales 36.49M
FCF (ttm) -80.83M
Book/sh 2.88
Cash/sh 2.34
Employees 141
Insider 10d —
IPO Nov 11, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.29
PEG —
P/S 5.99
P/B 1.26
P/C —
EV/EBITDA -0.96
EV/Sales 3.16
Quick Ratio 8.20
Current Ratio 8.42
Debt/Eq 19.90
LT Debt/Eq —
EPS (ttm) -1.98
EPS next Y -1.58
EPS Growth —
Revenue Growth -59.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-07
ROA -27.05%
ROE -52.26%
ROIC —
Gross Margin -243.48%
Oper. Margin -11.67%
Profit Margin 0.00%
Shs Outstand 60.42M
Shs Float 44.21M
Insider Own 15.14%
Instit Own 56.44%
Short Float 7.28%
Short Ratio 6.67
Short Interest 3.74M
52W High 5.55
vs 52W High -34.86%
52W Low 2.83
vs 52W Low 27.74%
Beta 1.25
Impl. Vol. 3.58%
Rel Volume 0.65
Avg Volume 540.45K
Volume 348.73K
Target (mean) $14.89
Tgt Median $12.00
Tgt Low $8.00
Tgt High $25.00
# Analysts 9
Recom Strong_buy
Prev Close $3.68
Price $3.62
Change -1.77%
About

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.89
Mean price target
2. Current target
$3.57
Latest analyst target
3. DCF / Fair value
$-24.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.57
Low
$8.00
High
$25.00
Mean
$14.89

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-17 reit HC Wainwright & Co. Buy → Buy $25
2025-11-12 main HC Wainwright & Co. Buy → Buy $25
2025-09-15 reit HC Wainwright & Co. Buy → Buy $30
2025-08-07 main Wedbush Outperform → Outperform $8
2025-04-08 reit HC Wainwright & Co. Buy → Buy $30
2025-03-13 main Canaccord Genuity Buy → Buy $12
2025-03-13 reit HC Wainwright & Co. Buy → Buy $30
2025-03-12 main Wells Fargo Overweight → Overweight $10
2025-03-12 reit Wedbush Outperform → Outperform —
2025-03-12 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-03 reit HC Wainwright & Co. Buy → Buy $30
2025-01-27 reit HC Wainwright & Co. Buy → Buy $30
2025-01-10 init Cantor Fitzgerald — → Overweight $6
2024-12-02 init Citigroup — → Buy $12
2024-11-14 main Canaccord Genuity Buy → Buy $14
2024-11-14 reit HC Wainwright & Co. Buy → Buy $30
2024-10-24 reit HC Wainwright & Co. Buy → Buy $30
2024-10-16 init Leerink Partners — → Outperform $15
2024-08-20 reit HC Wainwright & Co. Buy → Buy $30
2024-08-07 main Wedbush Neutral → Neutral $7
News
RSS: Latest VYGR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-02 SANDROCK ALFRED Chief Executive Officer — 11,511 $3.87 $44,548
2026-04-01 SHIFERMAN GREGORY L General Counsel — 50,000 $0.00 $0
2026-02-24 SANDROCK ALFRED Chief Executive Officer — 14,197 $3.79 $53,807
2026-02-24 JORGENSEN NATHAN D. Chief Financial Officer — 4,668 $3.77 $17,598
2026-02-24 SWARTZ ROBIN Chief Operating Officer — 6,458 $3.77 $24,347
2026-02-24 CARTER TODD ALFRED Officer — 4,174 $3.76 $15,694
2026-02-18 SANDROCK ALFRED Chief Executive Officer — 11,732 $3.41 $40,006
2026-02-18 SWARTZ ROBIN Chief Operating Officer — 3,882 $3.44 $13,354
2026-02-18 CARTER TODD ALFRED Officer — 3,301 $3.44 $11,355
2026-02-10 SANDROCK ALFRED Chief Executive Officer — 12,192 $3.78 $46,086
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
40.37
-49.53%
80.00
-68.00%
250.01
+511.16%
40.91
Operating Revenue
40.37
-49.53%
80.00
-68.00%
250.01
+511.16%
40.91
Operating Expense
172.22
+5.47%
163.29
+27.57%
127.99
+39.51%
91.74
Research And Development
134.67
+5.74%
127.37
+38.19%
92.17
+51.69%
60.76
Selling General And Administration
37.54
+4.52%
35.92
+0.27%
35.82
+15.63%
30.98
General And Administrative Expense
37.54
+4.52%
35.92
+0.27%
35.82
+15.63%
30.98
Other Gand A
37.54
+4.52%
35.92
+0.27%
35.82
+15.63%
30.98
Total Expenses
172.22
+5.47%
163.29
+27.57%
127.99
+39.51%
91.74
Operating Income
-131.84
-58.30%
-83.29
-168.26%
122.01
+340.01%
-50.84
Total Operating Income As Reported
-131.84
-58.30%
-83.29
-168.26%
122.01
+340.01%
-50.84
EBITDA
-127.78
-62.67%
-78.56
-162.12%
126.45
+383.24%
-44.65
Normalized EBITDA
-127.78
-62.67%
-78.56
-162.12%
126.45
+383.24%
-44.65
Reconciled Depreciation
4.06
-14.18%
4.73
+6.53%
4.44
-28.27%
6.19
EBIT
-131.84
-58.30%
-83.29
-168.26%
122.01
+340.01%
-50.84
Net Income
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Pretax Income
-119.58
-85.86%
-64.34
-148.11%
133.74
+388.28%
-46.39
Net Non Operating Interest Income Expense
10.62
-42.07%
18.33
+56.37%
11.72
+554.07%
1.79
Net Interest Income
10.62
-42.07%
18.33
+56.37%
11.72
+554.07%
1.79
Other Income Expense
1.65
+165.11%
0.62
+20633.33%
0.00
-99.89%
2.65
Other Non Operating Income Expenses
1.65
+165.11%
0.62
+20633.33%
0.00
-99.89%
2.65
Tax Provision
0.14
-78.35%
0.67
-52.77%
1.41
+8700.00%
0.02
Tax Rate For Calcs
0.00
-100.00%
0.00
+2000.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Net Income From Continuing Operation Net Minority Interest
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Net Income From Continuing And Discontinued Operation
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Net Income Continuous Operations
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Normalized Income
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Net Income Common Stockholders
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Diluted EPS
-2.04
-80.53%
-1.13
-138.05%
2.97
+345.45%
-1.21
Basic EPS
-2.04
-80.53%
-1.13
-136.69%
3.08
+354.55%
-1.21
Basic Average Shares
58.69
+1.77%
57.67
+34.05%
43.02
+12.16%
38.36
Diluted Average Shares
58.69
+1.77%
57.67
+29.39%
44.57
+16.20%
38.36
Diluted NI Availto Com Stockholders
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Total Other Finance Cost
-10.62
+42.07%
-18.33
-56.37%
-11.72
-554.07%
-1.79
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
252.28
-35.81%
393.05
+11.89%
351.28
+120.44%
159.36
Current Assets
202.69
-26.78%
276.81
-13.41%
319.68
+156.78%
124.50
Cash Cash Equivalents And Short Term Investments
196.45
-26.34%
266.68
+15.51%
230.88
+94.26%
118.85
Cash And Cash Equivalents
65.30
-8.50%
71.37
+3.73%
68.80
-30.47%
98.96
Cash Equivalents
51.16
-14.24%
59.66
-9.04%
65.59
-28.49%
91.72
Cash Financial
14.14
+20.75%
11.71
+264.43%
3.21
-55.59%
7.24
Other Short Term Investments
131.15
-32.85%
195.32
+20.51%
162.07
+714.89%
19.89
Receivables
2.92
-35.09%
4.49
-94.68%
84.45
+13116.74%
0.64
Accounts Receivable
1.76
+17.09%
1.50
-98.12%
80.15
0.00
Accrued Interest Receivable
1.00
-56.60%
2.31
+139.73%
0.96
+152.36%
0.38
Prepaid Assets
1.05
-62.03%
2.76
+59.91%
1.73
+121.57%
0.78
Hedging Assets Current
—
—
—
—
Other Current Assets
2.28
-20.77%
2.87
+9.36%
2.63
-37.92%
4.23
Total Non Current Assets
49.59
-57.34%
116.24
+267.89%
31.60
-9.35%
34.86
Net PPE
41.61
-12.69%
47.66
+58.86%
30.00
-10.01%
33.34
Gross PPE
60.77
-4.49%
63.62
+41.25%
45.04
-10.89%
50.55
Accumulated Depreciation
-19.15
-20.01%
-15.96
-6.12%
-15.04
+12.61%
-17.21
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.44
+4.50%
2.33
-11.09%
2.62
+12.52%
2.33
Construction In Progress
—
—
—
—
Other Properties
51.48
-6.07%
54.80
+55.19%
35.31
-0.98%
35.66
Leases
6.85
+5.60%
6.49
-8.71%
7.11
-43.40%
12.55
Investments And Advances
5.24
-92.02%
65.70
0.00
—
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
2.74
-4.80%
2.87
+80.41%
1.59
+5.15%
1.51
Total Liabilities Net Minority Interest
56.20
-39.76%
93.29
-18.85%
114.96
+14.58%
100.34
Current Liabilities
26.54
-46.69%
49.79
-22.82%
64.51
-11.13%
72.59
Payables And Accrued Expenses
8.02
-29.74%
11.41
-3.37%
11.81
+102.87%
5.82
Payables
5.01
+25.45%
4.00
+149.13%
1.60
-37.49%
2.57
Accounts Payable
5.01
+25.45%
4.00
+149.13%
1.60
-37.49%
2.57
Current Accrued Expenses
3.01
-59.47%
7.42
-27.33%
10.21
+213.45%
3.26
Pensionand Other Post Retirement Benefit Plans Current
9.09
+34.64%
6.75
+2.09%
6.61
+45.08%
4.56
Current Debt And Capital Lease Obligation
7.84
+8.48%
7.23
+125.84%
3.20
+12.99%
2.83
Current Capital Lease Obligation
7.84
+8.48%
7.23
+125.84%
3.20
+12.99%
2.83
Current Deferred Liabilities
1.59
-93.48%
24.39
-43.11%
42.88
-27.78%
59.38
Current Deferred Revenue
1.59
-93.48%
24.39
-43.11%
42.88
-27.78%
59.38
Total Non Current Liabilities Net Minority Interest
29.66
-31.82%
43.50
-13.78%
50.45
+81.85%
27.75
Long Term Debt And Capital Lease Obligation
28.66
-21.48%
36.50
+113.52%
17.09
-15.77%
20.29
Long Term Capital Lease Obligation
28.66
-21.48%
36.50
+113.52%
17.09
-15.77%
20.29
Non Current Deferred Liabilities
0.00
-100.00%
6.00
-81.45%
32.36
+401.69%
6.45
Non Current Deferred Revenue
0.00
-100.00%
6.00
-81.45%
32.36
+401.69%
6.45
Other Non Current Liabilities
1.00
+0.00%
1.00
+0.00%
1.00
-0.10%
1.00
Stockholders Equity
196.08
-34.59%
299.76
+26.84%
236.32
+300.41%
59.02
Common Stock Equity
196.08
-34.59%
299.76
+26.84%
236.32
+300.41%
59.02
Capital Stock
0.06
+7.27%
0.06
+25.00%
0.04
+15.79%
0.04
Common Stock
0.06
+7.27%
0.06
+25.00%
0.04
+15.79%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
59.05
+7.89%
54.73
+24.28%
44.04
+14.05%
38.61
Ordinary Shares Number
59.05
+7.89%
54.73
+24.28%
44.04
+14.05%
38.61
Additional Paid In Capital
641.89
+2.49%
626.30
+25.89%
497.51
+9.89%
452.71
Retained Earnings
-445.90
-36.70%
-326.18
-24.89%
-261.18
+33.63%
-393.51
Gains Losses Not Affecting Retained Earnings
0.03
+107.86%
-0.41
-747.92%
-0.05
+78.08%
-0.22
Other Equity Adjustments
0.03
+107.86%
-0.41
-747.92%
-0.05
+78.08%
-0.22
Total Equity Gross Minority Interest
196.08
-34.59%
299.76
+26.84%
236.32
+300.41%
59.02
Total Capitalization
196.08
-34.59%
299.76
+26.84%
236.32
+300.41%
59.02
Working Capital
176.15
-22.41%
227.02
-11.03%
255.18
+391.59%
51.91
Invested Capital
196.08
-34.59%
299.76
+26.84%
236.32
+300.41%
59.02
Total Debt
36.50
-16.53%
43.73
+115.46%
20.29
-12.25%
23.13
Capital Lease Obligations
36.50
-16.53%
43.73
+115.46%
20.29
-12.25%
23.13
Net Tangible Assets
196.08
-34.59%
299.76
+26.84%
236.32
+300.41%
59.02
Tangible Book Value
196.08
-34.59%
299.76
+26.84%
236.32
+300.41%
59.02
Available For Sale Securities
5.24
-92.02%
65.70
—
—
Duefrom Related Parties Current
0.15
-77.66%
0.68
-79.77%
3.34
+1200.00%
0.26
Investmentin Financial Assets
5.24
-92.02%
65.70
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-132.47
-765.23%
-15.31
-119.65%
77.92
+722.90%
-12.51
Cash Flow From Continuing Operating Activities
-132.47
-765.23%
-15.31
-119.65%
77.92
+722.90%
-12.51
Net Income From Continuing Operations
-119.72
-84.18%
-65.00
-149.12%
132.33
+385.14%
-46.41
Depreciation Amortization Depletion
4.06
-14.18%
4.73
+6.53%
4.44
-28.27%
6.19
Depreciation
4.06
-14.18%
4.73
+6.53%
4.44
-28.27%
6.19
Depreciation And Amortization
4.06
-14.18%
4.73
+6.53%
4.44
-28.27%
6.19
Other Non Cash Items
—
—
—
-2.47
Stock Based Compensation
14.79
+0.01%
14.79
+32.57%
11.15
+19.36%
9.34
Asset Impairment Charge
0.00
-100.00%
2.78
0.00
0.00
Operating Gains Losses
0.14
-72.35%
0.51
+186.52%
0.18
-52.79%
0.38
Gain Loss On Sale Of PPE
0.14
-72.35%
0.51
+186.52%
0.18
-52.79%
0.38
Change In Working Capital
-28.76
-182.51%
34.86
+152.37%
-66.56
-425.13%
20.47
Change In Receivables
0.27
-99.67%
81.31
+197.69%
-83.23
-17622.95%
0.47
Changes In Account Receivables
-0.26
-100.33%
78.65
+198.12%
-80.15
0.00
Change In Prepaid Assets
3.62
+237.69%
-2.63
-3556.58%
0.08
+103.86%
-1.97
Change In Payables And Accrued Expense
-1.48
-470.38%
-0.26
-103.23%
8.04
+795.93%
-1.16
Change In Accrued Expense
-2.50
+5.73%
-2.65
-129.44%
9.01
+386.12%
-3.15
Change In Payable
1.02
-57.48%
2.39
+348.65%
-0.96
-148.29%
1.99
Change In Account Payable
1.02
-57.48%
2.39
+348.65%
-0.96
-148.29%
1.99
Change In Other Working Capital
-28.81
+35.76%
-44.84
-576.33%
9.41
-60.33%
23.73
Change In Other Current Assets
4.87
+5.96%
4.60
+132.76%
1.98
-40.33%
3.31
Change In Other Current Liabilities
-7.23
-117.68%
-3.32
-17.19%
-2.83
+27.77%
-3.92
Investing Cash Flow
125.45
+232.24%
-94.86
+33.03%
-141.64
-1830.00%
-7.34
Cash Flow From Continuing Investing Activities
125.45
+232.24%
-94.86
+33.03%
-141.64
-1830.00%
-7.34
Net PPE Purchase And Sale
-2.60
+26.27%
-3.52
-8.14%
-3.26
-30.71%
-2.49
Purchase Of PPE
-2.60
+26.27%
-3.52
-8.14%
-3.26
-30.71%
-2.49
Sale Of PPE
—
—
—
—
Capital Expenditure
-2.60
+26.27%
-3.52
-8.14%
-3.26
-30.71%
-2.49
Net Investment Purchase And Sale
128.04
+240.18%
-91.34
+34.00%
-138.39
-2754.52%
-4.85
Purchase Of Investment
-133.93
+71.24%
-465.69
-107.92%
-223.97
-308.34%
-54.85
Sale Of Investment
261.97
-30.02%
374.35
+337.42%
85.58
+71.16%
50.00
Financing Cash Flow
0.82
-99.28%
114.02
+238.88%
33.65
+2931.08%
1.11
Cash Flow From Continuing Financing Activities
0.82
-99.28%
114.02
+238.88%
33.65
+2931.08%
1.11
Net Common Stock Issuance
0.00
-100.00%
112.78
+262.39%
31.12
0.00
Proceeds From Stock Option Exercised
0.82
-34.03%
1.24
-50.99%
2.52
+127.39%
1.11
Changes In Cash
-6.21
-261.34%
3.85
+112.79%
-30.08
-60.52%
-18.74
Beginning Cash Position
74.24
+5.46%
70.39
-29.94%
100.47
-15.72%
119.21
End Cash Position
68.04
-8.36%
74.24
+5.46%
70.39
-29.94%
100.47
Free Cash Flow
-135.06
-617.24%
-18.83
-125.22%
74.66
+597.75%
-15.00
Amortization Of Securities
-2.97
+62.69%
-7.97
-119.77%
-3.63
-22562.50%
-0.02
Common Stock Issuance
0.00
-100.00%
112.78
+262.39%
31.12
0.00
Issuance Of Capital Stock
0.00
-100.00%
112.78
+262.39%
31.12
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category